You are here: Industry Insights > WuXi STA

News List

CDMO WuXi STA Expands Footprint in Europe contractpharma
February 03, 2021
WuXi STA, a subsidiary of WuXi AppTec, has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland.
Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage prnasia
February 01, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has ...
Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact contractpharma
December 07, 2020
Tubulis, WuXi STA and WuXi Biologics have announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug conjugates (ADCs) towards IND-enabling studies.
WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility prnasia
January 05, 2020
Nucleic acid drugs have gradually become a hot area in the global innovative drug industry and many nucleic acid drugs have been approved by the U.S. FDA in recent years.
WuXi STA's New Drug Product Manufacturing Facility Passes First European MPA GMP Inspection en-cphi.cn
March 28, 2019
A subsidiary of WuXi AppTec - announces that its new drug product manufacturing facility in Shanghai Pilot Free Trade Zone has passed its first GMP inspection by the European Medical Products Agency (MPA).
WuXi STA and Ark Biosciences Sign CMC Development and Manufacturing Agreement fiercepharma
March 08, 2019
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Ark Biosciences, a global biotech company focusing on innovative drug discovery and development, especially in the area of viral infection and respiratory disease, today announce
WuXi STA, Ark Biosciences sign CMC development agreement biospectrumasia
March 06, 2019
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Ark Biosciences, a global biotech company focusing on innovative drug discovery and development, especially in the area of viral infection and respiratory disease, have announced
WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery pharmafocusasia
February 20, 2019
STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, and BioLingus, a Swiss biotech company, announce they have formed an exclusive technology and marketing collaboration for sublingual delivery.....
WuXi STA receives PAI from the US FDA biospectrumasia
May 08, 2018
This is the first time that WuXi STA's Changzhou facility has been inspected by the FDA
WuXi STA to build new R&D centre in Shanghai biospectrumasia
April 28, 2018
WuXi STA has already established an industry leading process development platform with over 1,000 scientists and five sites located in China and the United States.

Previous page 1 2 Next page